Authors and study year | Number of patients | Local control rate with primary radiotherapy (%) | Surgical salvage | Local control rate with primary radiotherapy and salvage surgery (%) | Survival | Follow-up time |
---|---|---|---|---|---|---|
Kraus 196674 and Perezmesa, | 13 | 0 (0) | 8/13 | 7 (53.8) | N.S. | N.S. |
Memula 198075 |
32 | 19 (59.4) | 6/13 | 25 (78.1) | 5-year 31% DFS | N.S. |
Medina 198430 |
12 | 7 (58.3) | 3/5 | 10 (83.3) | N.S. | At least 2 years |
Nair 1988 |
50 | 22 (44) at 3 years | 4/28 | N.S. | 3-year 44% DFS | At least 3 years |
Vidysagar |
107 | 55 (51.4) (residual disease in 19 patients, recurrence in 33 patients) | 20/52 | N.S. | 5-year DFS 49% | Range 6–60 months |
Jyothirmayi |
42 | 16 (38.1) (residual disease in 10 patients, recurrence in 16 patients) | 9/26 | N.S. | 5-year DFS 66% | Median 56 months (range 7–110) |
Koch 20013 |
33 | N.S. | N.S. | N.S. | 5-year 41.8% RSR | N.S. |
Authors and study year | Number patients of | Local control (%) | Survival | Follow-up time |
---|---|---|---|---|
Kraus 196674 and Perezmesa, | 64 | 55 (85.9) | N.S. | N.S. |
Medina 198430 |
90 | 74 (82.2) | N.S. | At least 2 years |
Jyothirmayi 19978 |
11 | N.S. | 5-year DFS 68% | Median (range 56 7months –110) |
Koch 20013 |
484 | N.S. | 5-year RSR 85.7% | N.S. |
Kang 200338 |
38 | 38 (100) at 3 years | 3-year OSR 94.7% | Median 37.5 13months –76) (range |
Walvekar 200917 |
101 | 80 (79.2) | 5-year DFS 77.6% | Median (range 4.61 0.5–years 14.3) |
Huang |
39 | 38 (97.4) | 5-year CSS 89.1% | Median 90 months (range, 13–171) |
Candau-Alvarez |
13 | 12 (92.3) | OSR 92.9% for a mean follow-up of 2 years | Mean 24.8 months (range 6–53) |
Franklyn |
22 | 21 (95.5) (recurrence in a patient with hybrid OVC) | N.S. | Median 24 months |